Shots:
- Health Canada has approved Agamree for the treatment of pts (≥4yrs) with Duchenne muscular dystrophy under priority review
- Approval was based on VISION-DMD study, which met its 1EP of Time to Stand (TTSTAND) velocity vs PBO at 24wks. of treatment, plus showed favorable safety & tolerability in pts
- Kye Pharma secured exclusive Canadian rights to Agamree for DMD & other potential uses via a Jul 2024 sub-licensing deal with Catalyst Pharmaceutical, Santhera’s partner, with Santhera earning royalties on Canadian sales, contributing to North American milestones
Ref: Jazz & Genentech | Image: Jazz Pharmaceuticals| Press Release
Related News:- Jazz Pharmaceuticals and Genentech Report the US FDA’s Approval of Zepzelca (Lurbinectedin) + Tecentriq (Atezolizumab) for ES-SCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
